Pennsylvania Adds Anxiety Disorders To Medical Marijuana Program

宾夕法尼亚州卫生部批准焦虑症和抽动症成年患者可申请购买医用大麻

2019-07-16 08:30:00 RTTNews

本文共658个字,阅读需2分钟

People suffering from anxiety disorders and Tourette Syndrome will soon be able to buy medical marijuana in Pennsylvania. Pennsylvania Department of Health Secretary Dr. Rachel Levine said in a statement that effective July 20, anxiety disorders and Tourette Syndrome will be approved as serious medical conditions in the state's medical marijuana program. The approval comes after recommendation of the Medical Marijuana Advisory Board and a review of medical research on the use of marijuana to treat these conditions. "I do not take this decision lightly, and do have recommendations for physicians, dispensary pharmacists and patients in terms of the use of medical marijuana to treat these conditions. For both conditions, medical marijuana is not first line treatment and should not replace traditional therapies but should be used in conjunction with them, when recommended by a physician," Dr. Levine said. Dr. Levine also advised patients to consult their healthcare providers to see if medical marijuana will be beneficial to them. Patients with anxiety disorders should continue to pursue counseling and therapy to manage their illness. Research has indicated that medical marijuana with low tetrahydrocannabinol or THC and high cannabidoil or CBD content are more effective for treatment of anxiety disorders and is recommended for short-term use. CBD is a naturally-occurring cannabinoid constituent of cannabis. It is a chemical in the marijuana plant often used for medicinal purposes, and does not have the intoxicating effects like those caused by THC. CBD is believed to relieve or ease symptoms related to health problems. "In addition, medical marijuana is not recommended to treat children and adolescents with anxiety disorders, as their brains are still developing," Dr. Levine said. Dr. Levine also warned that pregnant women with any of the approved serious medical conditions should not use medical marijuana as its impact on the fetus is unknown. According to the Pennsylvania Department of Health, there are nearly 111,000 active patients who have received certifications under Pennsylvania's medical marijuana program. Of the more than 1,600 physicians registered for the program, more than 1,160 have been approved as practitioners. The state's medical marijuana program was signed into law by Governor Tom Wolf on April 17, 2016.
患有焦虑症和抽动综合症的人很快就能在宾夕法尼亚州购买医用大麻。 宾夕法尼亚州卫生部长雷切尔·莱文博士在一份声明中说,从7月20日起,焦虑症和抽动综合症将被批准为该州医用大麻计划中的严重疾病。 在此之前,医用大麻咨询委员会提出了建议,并对使用大麻治疗这些疾病的医学研究进行了审查。 “我不会轻易作出这一决定,并就使用医用大麻治疗这些情况向医生、药房药剂师和病人提出建议。在这两种情况下,医用大麻不是一线治疗,不应取代传统疗法,但应在医生推荐的情况下与其结合使用。 Levine 博士还建议患者咨询他们的医疗保健提供者,看看医用大麻是否对他们有益。焦虑症患者应继续寻求咨询和治疗,以管理他们的疾病。 研究表明,低四氢氨基酚或 THC 、高大麻或 CBD 含量的医用大麻对治疗焦虑障碍更为有效,推荐短期使用。 CBD 是大麻的天然成分。它是一种常用于药用目的的大麻植物中的化学物质,不具有像 THC 引起的中毒作用。CBD 被认为可以缓解或缓解与健康问题有关的症状。 Levine 博士说:“此外,不建议使用医用大麻治疗患有焦虑障碍的儿童和青少年,因为他们的大脑仍在发育。” 莱文博士还警告说,有任何经批准的严重医疗状况的孕妇不应该使用医用大麻,因为它对胎儿的影响是未知的。 根据宾夕法尼亚州卫生部的数据,大约有111,000名活跃患者根据宾夕法尼亚州的医用大麻计划获得了认证。 在该项目注册的1600多名医师中,超过1160名已被批准为执业医师。 该州的医用大麻项目于2016年4月17日由州长汤姆·沃尔夫签署成为法律。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文